Pharnext to Present PXT864 Data at the Alzheimer's Association International Conference 2017
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that data related to PXT864, the Company’s lead PLEODRUG™, in development for the treatment of Alzheimer’s disease (AD), will be presented in two posters at the Alzheimer's Association International Conference 2017 (AAIC), July 16-20, in London, England.
Details are as follow:
PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice-daily. PXT864 acts through a new mechanism of action that targets metabolic imbalance in the brain of patients suffering from neurodegenerative diseases. PXT864’s most advanced indication is Alzheimer’s disease. Development in other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is also planned.
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
+33 (0)1 44 54 36 64
René Goedkoop, +33 (0)1 41 09 22 30
Chief Medical Officer
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
Media Relations (U.S.)
Financial Communication (France)
Emmanuel Huyn, +33 (0)1 44 71 20 40
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ANT-FINANCIAL20.6.2018 03:12 | pressemeddelelse
Ant Financial to Share Full Suite of AI Capabilities with Asset Management Companies
WA-AVALARA-INC19.6.2018 23:22 | pressemeddelelse
Avalara Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
UNILEVER19.6.2018 19:44 | pressemeddelelse
Unilever Calls on Content Creators and Distributors to Eradicate Stereotypes
AZ-UNIVERSAL-LASER19.6.2018 14:07 | pressemeddelelse
Universal Laser Systems Expands Its Materials Database with Henkel, Hexcel and Saint-Gobain Materials
NY-VALENCE-GROUP19.6.2018 13:59 | pressemeddelelse
Valence Advises Itaúsa on Sale of Brazilian Chemical Co Elekeiroz to H.I.G. Capital
CA-DOLE-FOOD-COMPANY19.6.2018 12:02 | pressemeddelelse
Dole Adds Industry Veteran Michael Solomon as President of Dole Fresh Vegetables
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum